Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Sanofi-Aventis Bristol-Myers Squibb |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00350038 |
The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.
Condition | Intervention | Phase |
---|---|---|
Hypertension Dyslipidemia |
Drug: Irbesartan Drug: Ciprofibrate |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Investigations of the Effects of Aprovel, Lipanor and Their Combination Onto the Endothelial Functions of Dyslipidemic Patients Measure by Laser Doppler Flow-Metry. |
Ages Eligible for Study: | 45 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | L_8759 |
Study First Received: | July 7, 2006 |
Last Updated: | January 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00350038 |
Health Authority: | Hungary: National Institute of Pharmacy |
Metabolic Diseases Ciprofibrate Irbesartan Vascular Diseases Angiotensin II |
Metabolic disorder Dyslipidemias Lipid Metabolism Disorders Hypertension |
Angiotensin II Type 1 Receptor Blockers Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |